Biochip: microarray-based diagnoses of Acute Myeloid Leukaemia

Crosslinks has produced a robust diagnostic analysis platform in collaboration with Skyline Diagnostics to deliver a state-of-the-art microarray-based prognoses for Acute Myeloid Leukaemia (AML) patients. The system enables speedy and accurate identification of Leukaemia sub-types so that the most effective subtype-specific treatments can be employed as quickly as possible.

The system is based on an innovative centralized architecture that offers key advantages over “on-device” processing:
Simpler development and validation and updating improves quality
Single secured environment ensures Signature IP protection

The AMLProfiler is entering final clinical trials in the second half of 2012 and represents a world-first in delivery of a complex prognostic device to FDA standards that takes advantage of modern networking to centralize processing in this way.
The platform is designed to be compliant with the stringent demands of the EU and United States Federal Drug Agency (FDA) and it is expected that it will be available – either as software as a service (SAAS) or as an “in house” solution – for other companies looking to develop similar products using novel diagnostic technologies such as microarrays or NGS.

The Biochip project is funded through the Netherlands CTMM (Centre for Translational Molecular Medicine) initiative.
CTMM Project page
Skyline